-

BostonGene Announces New Master Agreement with Leading Cancer Center in New York City

WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene Corporation today announced a master agreement with New York’s Memorial Sloan Kettering Cancer Center (MSK) that includes multiple research initiatives. The collaboration will support pre-clinical and clinical research activities at MSK which utilize BostonGene’s CLIA-certified and CAP-accredited high complexity molecular laboratory and advanced computational algorithms that identify and validate novel precision medicine approaches.

MSK is the world’s oldest and largest private cancer center. Its physicians and scientists work in close collaboration to provide patients with the best cancer care available while discovering more effective strategies to prevent, control, and ultimately cure cancer in the future.

The collaboration builds upon several ongoing research initiatives, including the targeted tumor-sequencing test MSK IMPACT™ study, in which BostonGene provides advanced analytics of next generation sequencing data to advance the clinical utility of genomic testing. This new master agreement enables further support of clinical trial correlative analysis to discover novel biomarkers and actionable targets. Additionally, BostonGene will perform comprehensive bioinformatics to validate hypothesis-driven research to identify targetable molecular alterations, evaluate gene expression and gene signatures, characterize cellular components in the tumor microenvironment, estimate tumor heterogeneity and predict neoantigens and tumor clonality.

“We share a vision with Memorial Sloan Kettering to develop innovative solutions and advance the adoption of precision medicine,” said Nathan Fowler, MD, Chief Medical Officer at BostonGene. “With BostonGene’s integration of scientific and clinical knowledge, we are equipped to support MSK in identifying personalized treatment options and improving care for patients.”

About BostonGene Corporation

BostonGene’s mission is to power healthcare’s transition to personalized medicine using AI-based molecular and immune profiling to improve the standard of care, accelerate research, and improve economics. BostonGene Tumor PortraitTM Tests reveal key drivers of each tumor, including immune microenvironment properties, actionable mutations, biomarkers of response to diverse therapies, and recommended therapies. Through these comprehensive analyses, BostonGene Tumor PortraitTM Tests generate a personalized roadmap for therapeutic decision-making for each cancer patient. For more information, visit BostonGene at http://www.BostonGene.com.

Contacts

Media:

BostonGene
Erin O’Reilly
+1-781-366-7049
Erin.Oreilly@BostonGene.com

BostonGene Corporation


Release Versions

Contacts

Media:

BostonGene
Erin O’Reilly
+1-781-366-7049
Erin.Oreilly@BostonGene.com

Social Media Profiles
More News From BostonGene Corporation

BostonGene to Present Multimodal AI Advances in Tumor-of-Origin Classification and Tumor Microenvironment Profiling at the ESMO AI & Digital Oncology Congress 2026

WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, developer of an AI model for tumor and immune biology, today announced its participation in ESMO AI & Digital Oncology Congress 2026 taking place November 16–18, 2026 in Berlin, Germany. The international forum unites oncologists, data scientists, and industry leaders to showcase advances in AI and computational biology across cancer care. BostonGene will demonstrate how its multimodal AI platform addresses critical oncology challenges, including...

BostonGene Showcases Biologically Grounded AI at ACR Convergence 2026 to Advance Precision Rheumatology and Autoimmune Disease Stratification

WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, developer of an AI model for tumor and immune biology, announced today that it will present new data demonstrating the application of its biologically grounded AI in non-oncology indications at the American College of Rheumatology (ACR) Convergence 2026. ACR Convergence 2026, the world's premier rheumatology event, will be held November 6–11 at the Orange County Convention Center in Orlando, Florida. BostonGene combines multimodal profiling with biol...

BostonGene Wins Three Gold Stevie® Awards

WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, developer of an AI model for tumor and immune biology, today announced that it has been awarded three Gold Stevie® Awards in the 2026 Stevie® Awards for Technology Excellence, taking top honors as Company of the Year, New Product of the Year, and Technology Breakthrough of the Year in Biotechnology. The awards recognize a fundamental shift in how oncology drugs are developed. Traditional AI approaches in drug development often rely on retrospective a...
Back to Newsroom